Assess whether to resubmit, meet, or pause the program (71cda8)

SITUATION A company with a CMC site change mid-review has biosimilar analytical similarity report in hand following a site-change that invalidates stability claims. Labeling negotiator must determine whether to resubmit, meet, or pause the program for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as To resubmit, meet, once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the program after a site-change that invalidates stability claims; To resubmit, meet, would over-claim this Pharmacovigilance extract. 3. A dual reading is still live in biosimilar analytical similarity report for labeling negotiator in a company with a CMC site change mid-review. 4. Biosimilar analytical similarity report is missing the fact labeling negotiator needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether biosimilar analytical similarity report supports the labeled claim labeling negotiator would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a site-change that invalidates stability claims and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for labeling negotiator - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for labeling negotiator in a company with a CMC site change mid-review